Images
Participants
Contact
“La Vanguardia”, together with other national and international media outlets, has published a news story about “Spark”, a project launched by a public-private consortium led by Iproteos, an IRB Barcelona and UB spin-off located at PCB. IRB Barcelona, CRG, the University of the Bask Country, and the biopharmaceutical company Ascil-Biopharma are also involved in the project.
The aim of Spark is to carry out the first preclinical stage of the development of a first-in-class drug to prevent, stop and reverse the progression of cognitive impairment associated with schizophrenia.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
